Clinical trial
Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History…
NCT00353067 · deCODE genetics, Industry · Suspended
Key facts
| NCT number | NCT00353067 |
|---|---|
| Title | Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Veliflapon (DG-031) in Reducing the Risk of Acute Cardiovascular Events in African American Patients With Coronary Artery Disease(The LTCAD Study). |
| Lead sponsor | deCODE genetics, Industry |
| Collaborators | Henry Ford Health System Duke University |
| Status | Suspended |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acute Coronary Syndrome |
| Intervention type | Drug |
| Interventions | veliflapon (DG-031) |
| Enrollment | 3,450 |
| Start date | May 1, 2006 |
| First posted | Jul 17, 2006 |
| Last update posted | Nov 29, 2006 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: